Background Recently, the addition of inhaled corticosteroid (ICS) to long-acting muscarinic
antagonist (LAMA) and long-acting beta-agonist (LABA) combination therapy has been …

Inhaled bronchodilators (alone or in combination) are the cornerstone of treatment for
symptomatic patients with COPD, either as initial/first-line treatment or for second …

Introduction Chronic obstructive pulmonary disease (COPD) is a treatable and preventable
disease characterised by persistent respiratory symptoms and chronic airflow limitation on …

In 2020, chronic obstructive pulmonary disease (COPD) was the fifth leading cause of death
in the United States excluding COVID-19, and its mortality burden has been rising since the …

Chronic obstructive pulmonary disease (COPD) is associated with major healthcare and
socioeconomic burdens. International consortia recommend a personalized approach to …

Although pharmacological treatment of COPD is codified in different guidelines and strategy
documents, there is abundant evidence of discrepancy between what they suggest and what …

Abstract Background In some RCTs comparing triple therapy with dual therapy in COPD,
there might be a bias resulting from the use of multiple inhaler devices. This meta-analysis …

There are more single inhaler device triple therapy available for COPD patients now.
However, the effect of long-term triple therapy fixed dose combination (FDC) on mortality …

Background and aim Real-life studies report discordant prescribing of inhaled triple therapy
(TT) among individuals with COPD. Guidelines recommend pulmonary rehabilitation (PR) …

Background: Some systematic reviews (SRs) on triple therapy (consisting of long-acting β2-
agonist, long-acting muscarinic antagonist, and inhaled corticosteroid, LABA/LAMA/ICS) for …